No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic

被引：36
作者：
Schwaiger, Julia [1 ]
Karbiener, Michael [1 ]
Aberham, Claudia [2 ]
Farcet, Maria R. [1 ]
Kreil, Thomas R. [1 ]
机构：
[1] Baxter AG, Global Pathogen Safety, Vienna, Austria
[2] Baxter AG, BioLife, Vienna, Austria
来源：
JOURNAL OF INFECTIOUS DISEASES | 2020年 / 222卷 / 12期
关键词：
primary immunodeficiency; SARS-CoV-2; SARS coronavirus 2 antibody titer; neutralizing antibodies; COVID-19; intravenous immunoglobulin; plasma; CORONAVIRUS; SERA;
D O I：
10.1093/infdis/jiaa593
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans, similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing, antibodies to the new species in humans is unclear. The question is particularly relevant for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment. Testing 54 intravenous immunoglobulin preparations, produced from plasma collected in Europe and the United States, confirmed highly potent neutralization of a seasonal coronavirus; however, no cross-neutralization of the new SARS-CoV-2 was seen.
引用
收藏
页码：1960 / 1964
页数：5
相关论文
共 50 条
  • [31] Antibody-mediated neutralization of SARS-CoV-2
    Gruell, Henning
    Vanshylla, Kanika
    Weber, Timm
    Barnes, Christopher O.
    Kreer, Christoph
    Klein, Florian
    IMMUNITY, 2022, 55 (06) : 925 - 944
  • [32] Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions
    Zheng, Yue
    Larragoite, Erin T.
    Williams, Elizabeth S. C. P.
    Lama, Juan
    Cisneros, Isabel
    Delgado, Julio C.
    Slev, Patricia
    Rychert, Jenna
    Innis, Emily A.
    Coiras, Mayte
    Rondina, Matthew T.
    Spivak, Adam M.
    Planelles, Vicente
    VIROLOGY JOURNAL, 2021, 18 (01)
  • [33] Reporting of child maltreatment during the SARS-CoV-2 pandemic in New York City from March to May 2020
    Rapoport, Eli
    Reisert, Hailey
    Schoeman, Emily
    Adesman, Andrew
    CHILD ABUSE & NEGLECT, 2021, 116
  • [34] Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions
    Yue Zheng
    Erin T. Larragoite
    Elizabeth S. C. P. Williams
    Juan Lama
    Isabel Cisneros
    Julio C. Delgado
    Patricia Slev
    Jenna Rychert
    Emily A. Innis
    Mayte Coiras
    Matthew T. Rondina
    Adam M. Spivak
    Vicente Planelles
    Virology Journal, 18
  • [35] SARS-CoV-2 Exposure and Seroprevalence of SARS-CoV-2 Antibodies among Medical Students in the First Phase of the Pandemic 2020-2021
    Landmesser, Patricia
    Weissbrich, Benedikt
    Peter-Kern, Martina
    Krone, Manuel
    Liese, Johannes
    Streng, Andrea
    GESUNDHEITSWESEN, 2024, 86 (04) : 311 - 314
  • [36] Lessons from SARS-CoV-2 Pandemic: Evolution, Disease Dynamics and Future
    Pandey, Saurabh
    Yadav, Bharat
    Pandey, Arvind
    Tripathi, Takshashila
    Khawary, Masuma
    Kant, Sashi
    Tripathi, Deeksha
    BIOLOGY-BASEL, 2020, 9 (06):
  • [37] Hypertension management: The lesson from the SARS-CoV-2 pandemic
    D'Elia, Lanfranco
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2025, 131 : 40 - 41
  • [38] Genomic and spatial epidemiology: lessons learned from SARS-CoV-2 pandemic
    Choi, Yangji
    De Ridder, David
    Greub, Gilbert
    CURRENT OPINION IN HIV AND AIDS, 2025, 20 (03) : 287 - 293
  • [39] A Glimpse for the subsistence from pandemic SARS-CoV-2 infection
    Rath, Santosh K.
    Dash, Ashutosh K.
    Sarkar, Nandan
    Panchpuri, Mitali
    BIOORGANIC CHEMISTRY, 2025, 154
  • [40] SARS-CoV-2 and Plasma Hypercoagulability
    Elisabeth Steadman
    Marina Fandaros
    Wei Yin
    Cellular and Molecular Bioengineering, 2021, 14 : 513 - 522
12345